Diaceutics PLC (DXRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Diaceutics PLC (DXRX) has a cash flow conversion efficiency ratio of 0.021x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX800.00K ≈ $97.34 USD) by net assets (GBX37.24 Million ≈ $4.53K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Diaceutics PLC - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Diaceutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Diaceutics PLC total liabilities for a breakdown of total debt and financial obligations.
Diaceutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Diaceutics PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CFI-Compagnie Foncière Internationale
PA:CFI
|
0.135x |
|
Dotdigital Group Plc
LSE:DOTD
|
0.145x |
|
Ordinary Fully Paid Deferred Settlement
AU:TASDA
|
N/A |
|
Doric Nimrod Air Three Ltd
LSE:DNA3
|
0.065x |
|
Bank Pembangunan Daerah Banten Tbk PT
JK:BEKS
|
0.265x |
|
Usha Martin Education & Solutions Limited
NSE:UMESLTD
|
0.019x |
|
Chinhung International Inc. Pfd. Series 2
KO:002787
|
-0.027x |
|
Cambium Networks Corp
NASDAQ:CMBM
|
0.204x |
Annual Cash Flow Conversion Efficiency for Diaceutics PLC (2016–2024)
The table below shows the annual cash flow conversion efficiency of Diaceutics PLC from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see DXRX market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX39.86 Million ≈ $4.85K |
GBX651.00K ≈ $79.21 |
0.016x | -49.19% |
| 2023-12-31 | GBX40.79 Million ≈ $4.96K |
GBX1.31 Million ≈ $159.51 |
0.032x | -73.18% |
| 2022-12-31 | GBX42.51 Million ≈ $5.17K |
GBX5.10 Million ≈ $620.04 |
0.120x | +754.82% |
| 2021-12-31 | GBX40.65 Million ≈ $4.95K |
GBX570.00K ≈ $69.35 |
0.014x | +123.02% |
| 2020-12-31 | GBX40.24 Million ≈ $4.90K |
GBX253.00K ≈ $30.78 |
0.006x | +120.19% |
| 2019-12-31 | GBX20.13 Million ≈ $2.45K |
GBX-627.05K ≈ $-76.29 |
-0.031x | +91.42% |
| 2018-12-31 | GBX2.63 Million ≈ $319.93 |
GBX-954.04K ≈ $-116.08 |
-0.363x | -144.41% |
| 2017-12-31 | GBX1.88 Million ≈ $228.47 |
GBX1.53 Million ≈ $186.66 |
0.817x | +22.70% |
| 2016-12-31 | GBX1.01 Million ≈ $123.16 |
GBX674.01K ≈ $82.01 |
0.666x | -- |
About Diaceutics PLC
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, which d… Read more